October 13, 2023 - VativoRx

VativoRx News

CMS Finalized a New Part B Rebate Model. The Rebates Are Owed to CMS.

Learn more →

October 23, 2026

VativoRx News

Employers Are Demanding Transparency on Pharmacy Rebates. Here’s What That Movement Doesn’t Cover.

Learn more →

October 9, 2026

Events

We’re Heading to SIIA 2026 in Phoenix

Learn more →

September 22, 2026

VativoRx News

It’s Vendor Review Season. Here’s One Question That Rarely Makes the Agenda.

Learn more →

September 18, 2026

VativoRx News

For Taft-Hartley Fund Trustees, Specialty Drug Cost Is a Fiduciary Question — Not Just a Budget One

Learn more →

August 28, 2026

VativoRx News

Most Employers Are Already Reviewing Medical Benefit Drug Claims. Fewer Are Doing Anything About What They Find.

Learn more →

August 14, 2026

VativoRx News

The Pharma Tariff Deadline Arrived. Here’s Where Things Actually Stand.

Learn more →

July 31, 2026

VativoRx News

The Rebate Blind Spot Hiding in Your Medical Benefit

Learn more →

July 20, 2026

VativoRx News

Self-Funded Employers Hold the Financial Risk on Specialty Drugs. Most Aren’t Capturing the Available Offset.

Learn more →

July 17, 2026

VativoRx News

The Specialty Drug Net Cost Number: How Confident Are You in What’s Inside It?

Learn more →

May 29, 2026

VativoRx News

Biosimilar Strategy Is Accelerating. The Medical Benefit Side of That Decision Is Mostly Unexamined.

Learn more →

May 15, 2026

VativoRx News

The Specialty Drug Rebate Gap Is Now Measurable. The Numbers Are Significant.

Learn more →

April 30, 2026

Resources & Insights

CMS Finalized a New Part B Rebate Model. The Rebates Are Owed to CMS.

Employers Are Demanding Transparency on Pharmacy Rebates. Here’s What That Movement Doesn’t Cover.

We’re Heading to SIIA 2026 in Phoenix

It’s Vendor Review Season. Here’s One Question That Rarely Makes the Agenda.

For Taft-Hartley Fund Trustees, Specialty Drug Cost Is a Fiduciary Question — Not Just a Budget One

Most Employers Are Already Reviewing Medical Benefit Drug Claims. Fewer Are Doing Anything About What They Find.

The Pharma Tariff Deadline Arrived. Here’s Where Things Actually Stand.

The Rebate Blind Spot Hiding in Your Medical Benefit

Self-Funded Employers Hold the Financial Risk on Specialty Drugs. Most Aren’t Capturing the Available Offset.

The Specialty Drug Net Cost Number: How Confident Are You in What’s Inside It?

Biosimilar Strategy Is Accelerating. The Medical Benefit Side of That Decision Is Mostly Unexamined.

The Specialty Drug Rebate Gap Is Now Measurable. The Numbers Are Significant.

Pharmacy Bulletin

Resources & Insights

All Resources

CMS Finalized a New Part B Rebate Model. The Rebates Are Owed to CMS.

Employers Are Demanding Transparency on Pharmacy Rebates. Here’s What That Movement Doesn’t Cover.

We’re Heading to SIIA 2026 in Phoenix

It’s Vendor Review Season. Here’s One Question That Rarely Makes the Agenda.

For Taft-Hartley Fund Trustees, Specialty Drug Cost Is a Fiduciary Question — Not Just a Budget One

Most Employers Are Already Reviewing Medical Benefit Drug Claims. Fewer Are Doing Anything About What They Find.

The Pharma Tariff Deadline Arrived. Here’s Where Things Actually Stand.

The Rebate Blind Spot Hiding in Your Medical Benefit

Self-Funded Employers Hold the Financial Risk on Specialty Drugs. Most Aren’t Capturing the Available Offset.

The Specialty Drug Net Cost Number: How Confident Are You in What’s Inside It?

Biosimilar Strategy Is Accelerating. The Medical Benefit Side of That Decision Is Mostly Unexamined.

The Specialty Drug Rebate Gap Is Now Measurable. The Numbers Are Significant.

Pharmacy Bulletin